Ocugen’s latest analyst update comes with no change in its price target, leaving existing expectations intact for now. With no new analyst commentary accompanying this update, investors are left to ...

A month has gone by since the last earnings report for Ocugen (OCGN). Shares have lost about 10.7% in that time frame, underperforming the S&P 500. But investors have to be wondering, will the recent ...

Ocugen OCGN is advancing a retinal pipeline built around durability and breadth. Its focus is a modifier gene therapy ...

Ocugen frames 2026 as pivotal because it expects meaningful milestones across all three core ocular programs in the same year ...

Ocugen faces cash burn and dilution risks, but upcoming eye gene therapy data and planned filings through 2027 could shape its next phase.

For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Is Ocugen (OCGN) one of those stocks right now? A quick glance ...

Discover high-conviction stock picks and new investing opportunities with the TipRanks Smart Investor Newsletter Ocugen ( (OCGN)) has shared an update. Ocugen, Inc. reported that Chief Accounting ...

Ocugen Inc (NASDAQ:OCGN) shares are trading lower by 11% to $1.25 Thursday morning after the company announced the pricing of its public offering of 30,434,783 shares of common stock at $1.15 per ...

Ocugen Inc (NASDAQ:OCGN) shares are trading higher by 25.6% to $2.06 during Monday’s session. The stock is trading higher, potentially on upward momentum, after the Third Circuit Court of Appeals last ...

View Ocugen Inc OCGN stock quote prices, financial information, real-time forecasts, and company news from CNN.